Trail Ridge Investment Advisors LLC Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Trail Ridge Investment Advisors LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,556 shares of the medical research company’s stock, valued at approximately $1,783,000. Thermo Fisher Scientific accounts for 0.8% of Trail Ridge Investment Advisors LLC’s holdings, making the stock its 23rd largest holding.

Several other institutional investors have also recently made changes to their positions in the company. High Note Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth about $25,000. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price objective on the stock. Piper Sandler lifted their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Royal Bank Of Canada raised their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 73,493 shares of company stock valued at $43,950,381 in the last 90 days. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $628.69 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a 50 day moving average price of $545.64 and a 200-day moving average price of $509.60. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm has a market capitalization of $232.46 billion, a PE ratio of 33.82, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the company posted $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.